Imagion Biosystems has announced “Appendix 3B, New issue announcement, application for quotation of additional securities and agreement.”
Read Appendix 3B.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce